Biomarker-Driven Lung Cancer

Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are a promising class of anticancer agents that may present effective alternatives to standard therapy for women with advanced, refractory, or relapsed hormone receptor (HR)‒positive breast cancer.

A number of highly effective cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are currently in development as treatments for patients with metastatic breast cancer.

Inhibition of cyclin-dependent kinase 4 (CDK4) and CDK6 has been extensively studied in estrogen receptor (ER)‒driven breast cancer.

More than 20 years have passed since the cyclin-dependent kinases 4 (CDK4) and CDK6 were discovered to drive oncogenesis in several cancer types.

An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy.

Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.

Immunohistochemistry can effectively be used for the identification of ROS1 gene alterations to ascertain eligibility for the targeted therapy crizotinib for patients with non-small cell lung cancer.

Clovis has stopped clinical development of rociletinib, its once promising EGFR inhibitor for the treatment of patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC).

James L. Mulshine, MD, professor, acting dean, Graduate College, Department of Internal Medicine, Rush Medical College, Rush University, discusses the worldwide differences in screening for lung cancer.

The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer.

Mature data from both the phase I and phase II portions of the AURA study paints a bright, hopeful future for the use of third-generation TKI osimertinib (AZD9291) in patients with EGFR T790M-mutant non-small cell lung cancer.

mNSCLC with Mark Kris, MD and Mark Socinski, MD

Treatment with the novel multikinase inhibitor entrectinib achieved objective responses in 79% of patients with solid tumors associated with NTRK, ROS-1, or ALK rearrangements.

The FDA has approved afatinib for the treatment of patients with advanced squamous cell non-small cell lung cancer following progression on platinum-based chemotherapy.

Patients with non-small cell lung cancer (NSCLC) who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 against the accelerated approval of rociletinib for patients with metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) who have previously received an EGFR-targeted therapy.